Drug intelligence / Profile preview

2-(4-chlorophenyl)-5-quinoxalinecarboxamide

Development stage: Preclinical
Modality: Small Molecules

Overview

2-(4-Chlorophenyl)-5-quioxalinecarboxamide is an experimental small molecule belonging to the quinoxaline class. It acts as a potent inhibitor of poly [ADP-ribose] polymerase 1 (PARP1), an enzyme involved in DNA repair processes such as base excision repair. By inhibiting PARP1, this compound may disrupt DNA damage response pathways and has been investigated for potential anticancer activity. The compound is not approved for clinical use and has primarily been studied as a research tool or discovery agent[1][2][8].

Other names: 2-(4-Chlorophenyl)-5-quioxalinecarboxamide3-(4-chlorophenyl)quinoxaline-5-carboxamideCNQ

Targets

PARP1 (Poly (adp-ribose) polymerase 1)

Beyond the preview

Go deeper on 2-(4-chlorophenyl)-5-quinoxalinecarboxamide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 2-(4-chlorophenyl)-5-quinoxalinecarboxamide.

Explore the full profile